Labopharm May Conduct Additional Trial To Support Tramadol NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. regulators questioned Labopharm’s statistical methods in a May 30 “approvable” letter, the opioid analgesic’s second.